三诺生物 reported revenue of ¥2.54B for the period ended 2026-06-30, +12.1% year on year. Net income was ¥0.23B, a 8.9% net margin on a 53.2% gross margin. The largest revenue line is 血糖监测系统 at 74% of the total. Free cash flow for the period was ¥0.16B.
| Item | Amount | Y/Y |
|---|---|---|
| Revenue | ¥2.54B | +12.1% |
| Gross profit | ¥1.35B | — |
| Operating income | ¥0.27B | — |
| Net income | ¥0.23B | +24.5% |
| Gross margin | 53.2% | Net margin 8.9% |
| Revenue Q/Q | +4.7% | — |
| Segment | Revenue | Share |
|---|---|---|
| 血糖监测系统 | ¥1.88B | 74.1% |
| 即时检测POCT产品 | ¥0.43B | 17.0% |
| 辅助产品及其他 | ¥0.23B | 8.9% |
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | ¥1.19B | 46.8% |
| R&D | ¥0.12B | 4.9% |
| SG&A | ¥0.93B | 36.5% |
| Tax & other | ¥0.04B | 1.5% |
| Item | Amount |
|---|---|
| Total assets | ¥5.95B |
| Total liabilities | ¥2.55B |
| Shareholders' equity | ¥3.39B |
| Equity / assets | 57.1% |
| Operating cash flow | ¥0.19B |
| Capital expenditure | ¥0.03B |
| Free cash flow | ¥0.16B |
| Cash conversion (OCF / net income) | 105% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
富春股份 ・ 海峡创新 ・ ST长方 ・ 同有科技 ・ 聚飞光电 ・ 云意电气 ・ 裕兴股份 ・ 远方信息 ・ 慈星股份 ・ 宜通世纪 ・ 任子行 ・ 天山生物
Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies